The $117.1M net proceeds extend IMMX's cash runway significantly for NXC-201 development, but the ~30-40% dilution at a $11.00 price point creates near-term overhang. Monitor for NEXICART-2 clinical data updates as the primary catalyst for share price recovery; the BTD/RMAT designations provide regulatory optionality that could offset dilution if efficacy data is compelling.
Price Chart
Executive Summary
Immix Biopharma priced a $125 million underwritten offering of 11,363,637 shares at $11.00 per share, with net proceeds of approximately $117.1 million to fund NXC-201 development and working capital. The offering, led by J.P. Morgan with participation from major institutional investors, represents significant near-term dilution of roughly 30-40% based on pre-offering share count, but provides a substantial cash runway for a clinical-stage biotech with a lead CAR-T candidate that has FDA Breakthrough Therapy and RMAT designations.
Key Facts
- Priced 11,363,637 shares at $11.00 per share for gross proceeds of $125 million
- Net proceeds estimated at approximately $117.1 million after underwriting discounts and expenses
- Underwriter purchase price is $10.34 per share (6% discount to public offering price)
- J.P. Morgan is sole book-running manager; offering includes Eventide, Janus Henderson, Ridgeback, Wellington
- Proceeds to fund NXC-201 (BCMA-targeted CAR-T) development, working capital and general corporate purposes
- NXC-201 has FDA Breakthrough Therapy Designation, RMAT designation, and Orphan Drug Designation
- 90-day lock-up agreements with officers and directors restrict insider sales
- Offering expected to close September 30, 2026
Financial Impact
Dilutive offering of $125M gross / ~$117.1M net proceeds; 11,363,637 new shares represent substantial dilution to existing shareholders
Risk Factors
- Substantial dilution of ~30-40% to existing shareholders from the 11.36M new shares
- Clinical-stage biotech with no approved products; NXC-201 development and regulatory outcomes are binary
- Potential for further dilution if additional capital is needed before NXC-201 reaches commercialization
- Stock price may trade below the $11.00 offering price post-close, pressuring near-term returns
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-045143 |
| Exhibit: ex5-1.htm | 0001493152-26-045143 |
| Exhibit: ex99-1.htm | 0001493152-26-045143 |
| Document: form8-k.htm | 0001493152-26-045143 |
| Document: 0001493152-26-045143-index-headers.html | 0001493152-26-045143 |
| Document: 0001493152-26-045143-index.html | 0001493152-26-045143 |
| Document: 0001493152-26-045143.txt | 0001493152-26-045143 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | 8-K | $10.23 $9.29 | ▲ +9.19% | ▲ +10.49% | $8.13 (+20.53%) |
Sep 29, 2026 27d ago | 424B5 | $10.54 $9.64 | ▲ +8.54% | ▲ +10.49% | $8.13 (+22.87%) |
Sep 29, 2026 27d ago | 8-K | $10.54 $9.64 | ▼ −8.54% | ▼ −10.49% | $8.13 (−22.87%) |
Jul 20, 2026 14w ago | 8-K | $8.80 $8.52 | ▼ −3.18% | ▼ −2.76% | $8.13 (−7.61%) |
May 21, 2026 22w ago | 8-K | $8.78 $9.22 | ▼ −5.01% | ▼ −3.35% | $8.13 (+7.40%) |
May 21, 2026 22w ago | Press Release | $8.67 $9.00 | ▲ +3.81% | ▲ +1.96% | $8.13 (−6.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers